First semaglutide generics launched in India

India is the first market where semaglutide generics are entering at scale, providing a benchmark for how competition, pricing, and supply chains evolve once multiple players launch simultaneously. 13 companies have confirmed generic semaglutide launches in India (Figure 1). Including Novo Nordisk as the originator, this results in 14 active players in total:

• Abbott
• Alkem Laboratories
• Dr. Reddy’s
• Eris Lifesciences
• Emcure Pharmaceuticals
• Glenmark Pharmaceuticals
• Lupin
• MSN
• Natco Pharma
• Novo Nordisk
• Sun Pharma
• Torrent Pharmaceuticals
• USV
• Zydus

In addition, more than 20 companies have sourced semaglutide API in the past 12 months, suggesting a second wave of entrants that are either delayed or taking a wait-and-see approach amid downward pricing pressure (Figure 1).

Generic prices show strong downward trend

Generic prices in India are significantly below originator levels. At initial launch, the price gap reached up to 35x, but following recent price cuts by Novo Nordisk, this has narrowed to 7–22x lower than the originator domestically.

Compared to the U.S., generics in India are up to 170x lower than the upper end of U.S. price ranges and 40–45x lower than the 350 USD/month “most favored nation” benchmark.

Current monthly price ranges of generics show how quickly price erosion is setting in (Figure 2):

• Lowest generic entry point: 8–21 USD/month (Sun Pharma)
• Other generics: 14–48 USD/month (Eris Lifesciences, Natco Pharma, Glenmark Pharmaceuticals, Alkem Laboratories, Lupin, Zydus, Torrent Pharmaceuticals, Dr. Reddy’s, USV)
• Emcure Pharmaceuticals (in-licensed from Novo Nordisk): 94 USD/month

In response, originator Novo Nordisk has already adjusted pricing in India. The originator price range shifted downward by 35–37% across both the lower and upper end, moving from 94–277 USD/month to 60–175 USD/month within two weeks of generic entry.

Novo Nordisk monthly prices as benchmark (Figure 2):

• India: 94–277 USD/month → reduced to 60–175 USD/month after generic entry (Economic Times, March 31, 2026)
• U.S.: 1,028–1,349 USD/month (upper range), 350 USD/month (“most favored nation” price)

Auto-injector pens dominate India’s generic entries

Auto-injector pens have emerged as the dominant dosage form for generic semaglutide, with 11 out of 13 companies choosing this format (Figure 3):

• 11 companies have launched auto-injector pens (Abbott, Alkem Laboratories, Dr. Reddy’s Laboratories, Emcure Pharmaceuticals, Glenmark Pharmaceuticals, Lupin, MSN, Sun Pharma, Torrent Pharmaceuticals, USV, Zydus)
• 3 companies are using a vial-based format (Eris Lifesciences, Glenmark Pharmaceuticals, Natco Pharma – announced a pen for April)
• 1 company has launched the oral tablet (Torrent Pharmaceuticals)

Two companies are taking a broader approach:

• Glenmark Pharmaceuticals: vial and pen
• Torrent Pharmaceuticals: pen and tablet

China is powering India’s semaglutide generic entries

Chinese manufacturers are a critical part of the supply chain behind Indian semaglutide launches – not only at the API level, but also upstream in intermediates and key starting materials (Figure 4):

• 8 companies (61%) show partial or full dependence on China
  • 3 companies (23%) are fully reliant on China for API manufacturing
  • 5 companies (38%) source APIs from two countries – but all still include China
• Only 4 companies (31%) show no direct China exposure at the API manufacturing level
  • Abbott and Emcure via Novo Nordisk in-licensing from Denmark
  • MSN and Zydus with API manufacturing in India

However, China dependency remains present even in some of these cases – just further upstream. For example, Zydus sources key starting materials from China.

Potential market entries in Brazil

Using the QYOBO platform, we have identified 13 companies planning or preparing to launch semaglutide in Brazil, based on trade flows, regulatory data from Anvisa, and public news integrated on the QYOBO News Hub (Figure 5).

These include both global and local players (Figure 6). Notably, four of these companies are already part of the first launch wave in India: Dr. Reddy’s, Lupin, Sun Pharma, Torrent Pharmaceuticals. The QYOBO platform also provides visibility into supply chains behind these market entries (Figure 6). Here as well, China has the largest footprint in both API and key starting material manufacturing.

Examples such as Libbs Farmacêutica, source both the API and key starting material from Sinopep in China, highlighting once again the central role of China in peptide manufacturing.

As semaglutide generics expand beyond India into markets such as Brazil, Canada, and China, the patterns observed in India – rapid price erosion and strong reliance on China for API and KSM manufacturing – are likely to repeat. Stay up2date on the latest developments through the QYOBO platform and make decisions with confidence.

API prices follow basic supply-demand patterns

QYOBO platform data provide evidence that competition amongst suppliers plays an important role in API pricing. This observation reflects basic supply and demand economics: when the number of active manufacturers rises and supply outpaces demand, market leverage shifts to buyers. As competition intensifies, prices fall – often to levels that are unsustainable for marginal producers (typically higher-cost or subscale suppliers). Over time, these suppliers exit, bringing supply and demand back into balance.

In an analysis of 1,200 APIs, 26% showed price decreases in at least four out of five years – with 6% declining every single year (Figure 1). Only 9% of APIs experienced consistent price increases, rising in at least four of the last five years. These movements strongly correlate with the number of active manufacturers. APIs with declining prices had between 15 and 20 international manufacturers, whereas those with increasing prices only had an average of 4 to 9 manufacturers, which suggests that the optimal range for a balanced market lies between 9 and 12 internationally active manufacturers – a level where neither buyers nor suppliers hold excessive leverage.

Together, these findings show that scale brings both cost and price stability advantages, yet most market participants operate in smaller segments where data transparency and negotiation power remain crucial to achieving competitive pricing.

Geography matters, but not alone

Location matters, but it’s not the only factor. QYOBO data across 165 APIs shows that 49% have higher prices in Western regulated markets (WRM) than in the rest of the world (ROW), with a median price premium of 43% (Figure 4). For about 30% of APIs, prices are similar in both regions (within ±10%). Interestingly, 21% of APIs are more expensive in the ROW, showing 25% price premium vs. Western regulated markets.

This divergence underscores how demand-side factors – such as sudden order surges, inventory buildup, or short-term market disruptions such as temporary tariffs – can temporarily drive API prices upward even when input costs remain stable.

By mapping these interdependencies, the QYOBO platform enables users to distinguish between price movements driven by input-cost fluctuations and those resulting from market dynamics at the API level, providing a clearer view of underlying supply chain pressures and pricing drivers.

Turn price transparency into advantage

Across manufacturers, volumes, geographies, and upstream cost drivers, the picture is clear: current and reliable visibility into pharmaceutical raw material prices is critical to stay competitive in a fast-moving pharma market. The QYOBO platform provides this clarity at scale.